Live Feed

SHELL PLC FIRST QUARTER 2026 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS June 15, 2026 The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the first quarter 2026 interim dividend, which was announced on May 7, 2026 at US$0.3906 per ordinary share. Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by June 8, 2026 will be entitled to a dividend of US$0.3906, €0.3381 or 29.18p per ordinary share, respectively. Absent any valid election to the contrary, persons holding the

CHARLOTTE, North Carolina, June 15, 2026 (GLOBE NEWSWIRE) -- Magnera Corporation (NYSE:MAGN) today announced the sale of its Caerphilly, UK operations to Polyart Group, a Prudentia Capital holding. Following a strategic portfolio review of its manufacturing technologies, products, and markets served, Magnera initiated an evaluation of strategic alternatives for its Caerphilly business that produces metallized paper for various end market applications, including premium labels, gift wrap and food packaging. The evaluation initiated a sale process for the operations, resulting in an agreement with the Polyart Group to purchase 100% of the shares of the Caerphilly business. "We are deeply g

HOUSTON, June 15, 2026 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE:EGY, LSE: EGY)) ("Vaalco" or the "Company") announced positive operational updates offshore Gabon regarding the ongoing drilling program, including impressive initial well results on the Ebouri-5H well and mobilization of the rig to the SEENT platform. Additionally, the Company provided a positive update on the first well completed in the 2026 onshore Egypt drilling program. Operational Highlights: Successfully drilled, completed and placed on production the Ebouri-5H development well at the top of the structure with a lateral of 300 meters of net pay in high-quality Gamba sands; Achieved excellent initial flow ra

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem New software capabilities support standardized analysis and reporting across digital PCR workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across li

As European and allied forces accelerate modernization efforts in response to evolving operational threats, Oshkosh Defense LLC, an Oshkosh Corporation (NYSE:OSK) business, will showcase proven tactical mobility solutions at Eurosatory 2026 designed to support interoperability, distributed operations and future battlefield requirements, without the risk and long development timelines of entirely new vehicle programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614504023/en/Oshkosh Defense Hybrid Electric Joint Light Tactical Vehicle (eJLTV). For decades, Oshkosh Defense has supported allied military forces with heavy, medi

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effectsNew analyses showed patients in mitapivat arm had clinically meaningful reduction in transfusion burden compared with placeboPatients in mitapivat arm who achieved hemoglobin response had clinically meaningful benefits across measures of sickle cell pain crises, fatigue, and other patient-reported outcomesMitapivat was well-tolerated, with a safety profile consistent with previous trials of mitapivat in sickle cell diseaseCompany to host investor conference call and webcast today at 9:00 a.m. ET (3:00 p.m. CEST) CAMBRIDGE, Mass., June 13, 2026 (GLO

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --    -- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS -- -- Company to hold conference call on Saturday, June 13, at 8 a.m. CT, 9 a.m. ET -- BOSTON, June 13, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced preliminary data from a Phase 2 trial

4 - PROCORE TECHNOLOGIES, INC. (0001611052) (Issuer)

4 - IonQ, Inc. (0001824920) (Issuer)

4 - IonQ, Inc. (0001824920) (Issuer)

4 - IonQ, Inc. (0001824920) (Issuer)

4 - GARMIN LTD (0001121788) (Issuer)

4 - IonQ, Inc. (0001824920) (Issuer)

4 - Acushnet Holdings Corp. (0001672013) (Issuer)

4 - United Parks & Resorts Inc. (0001564902) (Issuer)

4 - United Parks & Resorts Inc. (0001564902) (Issuer)

4 - United Parks & Resorts Inc. (0001564902) (Issuer)

4 - KULR Technology Group, Inc. (0001662684) (Issuer)

3 - KULR Technology Group, Inc. (0001662684) (Issuer)

4 - ROKU, INC (0001428439) (Issuer)